ANOTHER CASE OF THE RICH PLUNDERING AND MURDERING, KEEPING
THEIR ILL GOT GAINS AND GIVING THE MIDDLE FINGER TO JAIL TIME!
The Sackler family was once listed among the
nation’s wealthiest by Forbes magazine. A 2019 court filing said they had made
up to $13 billion over the years from the blockbuster drug…
OxyContin maker Purdue Pharma to plead to 3
criminal charges
MICHAEL BALSAMO and GEOFF MULVIHILL
October 21, 2020
WASHINGTON (AP) — Purdue Pharma, the company that makes
OxyContin, the powerful prescription painkiller that experts say helped touch
off an opioid epidemic, will plead guilty to three federal criminal charges as
part of a settlement of more than $8 billion, Justice Department officials
announced Wednesday.
The company will plead guilty to three counts, including
conspiracy to defraud the United States and violating federal anti-kickback
laws, the officials said. The resolution will be detailed in a bankruptcy court
filing in federal court.
The deal does not release any of the company’s executives or
owners — members of the wealthy Sackler family — from criminal liability, and a
criminal investigation is ongoing. One state attorney general said the
agreement fails to hold the Sacklers accountable, while family members said they
had acted “ethically and lawfully."
The settlement is the highest-profile display yet of the
federal government seeking to hold a major drugmaker responsible for an opioid
addiction and overdose crisis linked to more than 470,000 deaths in the country
since 2000.
“Purdue deeply regrets and accepts responsibility for the
misconduct detailed by the Department of Justice in the agreed statement of
facts,” Steve Miller, who became chairman of the company’s board in 2018, said
in a statement. No members of the Sackler family remain on that board, though
they still own the company.
Family members, in a statement, expressed “deep compassion
for people who suffer from opioid addiction and abuse and hope the proposal
will be implemented as swiftly as possible to help address their critical
needs.”
The deal comes less than two weeks before a presidential
election where the opioid epidemic has taken a political back seat to the
coronavirus pandemic and other issues. It does give President Donald Trump’s
administration an example of action on the addiction crisis, which he promised
early in his term.
But to Massachusetts Attorney General Maura Healey, the
Justice Department “failed” and she said in a statement that she was not done
with either Purdue or the Sacklers. “Justice in this case requires exposing the
truth and holding the perpetrators accountable, not rushing a settlement to
beat an election,” she said.
Ed Bisch, who lost his 18-year-old son to an OxyContin
overdose nearly 20 years ago, said he wants to see people associated with
Purdue prosecuted. “The fact that they day this doesn't grant anyone immunity,
I'm heartened by that,” he said after the deal was announced.
As part of the resolution, Purdue is admitting that it
impeded the Drug Enforcement Administration by falsely representing that it had
maintained an effective program to avoid drug diversion and by reporting
misleading information to the agency to boost the company's manufacturing
quotas, the officials said.
Purdue is also admitting to violating federal anti-kickback
laws by paying doctors, through a speaking program, to induce them to write
more prescriptions for the company’s opioids and for using electronic health
records software to influence the prescription of pain medication, according to
the officials.
Purdue will make a direct payment to the government of $225
million, which is part of a larger $2 billion criminal forfeiture. In addition
to that forfeiture, Purdue also faces a $3.54 billion criminal fine, though
that money probably will not be fully collected because it will be taken
through a bankruptcy, which includes a large number of other creditors. Purdue
will also agree to $2.8 billion in damages to resolve its civil liability.
Purdue would transform into a public benefit company, meaning
it would be governed by a trust that has to balance the trust’s interests
against those of the American public and public health, officials said. The
Sacklers would not be involved in the new company and part of the money from
the settlement would go to aid in medication-assisted treatment and other drug
programs to combat the opioid epidemic, the officials said.
As part of the plea deal, the company admits it violated
federal law and “knowingly and intentionally conspired and agreed with others
to aid and abet” the dispensing of medication from doctors “without a
legitimate medical purpose and outside the usual course of professional
practice,” according to a copy of the plea agreement obtained by the AP.
First lady Melania Trump, who has focused many of her public
efforts on health issues such as this epidemic, tweeted that the agreement was
“another big step in defeating” the crisis.
But even before the deal was announced, it was facing
resistance from state attorneys general, Democratic members of Congress and
advocates who wrote Attorney General William Barr asking him not to make the
bargain with the company and the family. They said it does not hold them
properly accountable and they raised concerns about some of the details.
The Sackler family has already pledged to hand over the
company itself plus at least $3 billion to resolve thousands of suits against
the Stamford, Connecticut-based drugmaker. The company declared bankruptcy as a
way to work out that plan, which could be worth $10 billion to $12 billion over
time. Family members said in their statement that the company’s value is more
than twice as much as they profited from OxyContin.
About half the states oppose that settlement, and also wrote
Barr to ask him not to make the federal deal that includes converting Purdue
into a public benefit corporation. They say it would be wrong for
governments to rely on earnings from the sale of more OxyContin to fund
programs to mitigate the toll of an opioid crisis wrought by prescription drugs
as well as heroin and illicitly produced fentanyl.
The Sackler family was once listed among the
nation’s wealthiest by Forbes magazine. A 2019 court filing said they had made
up to $13 billion over the years from the blockbuster drug, though a lawyer said they brought in
far less after taxes and reinvestment in the company.
Until recently, the family’s name was on museum galleries and
educational programs around the world because of gifts from family members. But
under pressure from activists, institutions from the Louvre in Paris to Tufts
University in Massachusetts have dissociated themselves from the family in the
last few years.
Oxycontin
maker Purdue Pharma will plead guilty to three criminal charges in $8billion
plea deal that does NOT release the Sacklers from criminal liability BUT does
mean the wealthy owners will lose any stake in the pharma giant
·
DOJ officials said the company will plead
guilty to three counts of criminal charges filed Wednesday in federal court in
New Jersey
·
Charges include conspiracy to defraud the
United States and violating federal anti-kickback laws, officials said
·
The anti-kickback relates to a 2015 deal of
almost $1 million that Purdue made with Practice Fusion to encourage doctors to
prescribe opioids
·
United States Deputy Attorney General.
Jeffrey A Rosen announced the deal in a press conference Wednesday as he vowed
to 'turn the tide on the opioid crisis'
·
Rosen said the deal is still subject to
bankruptcy court approval
·
The deal does not release any of the
company's executives or owners - members of the wealthy Sackler family - from
criminal liability
·
However, if the bankruptcy court approves the
resolution, the Sackler family will lose any stake in the pharma giant and the
company will be dissolved
·
Its assets will be re-purposed into a public
company instead
·
OxyContin is the powerful prescription
painkiller that experts have blamed for helping spark America's opioid
epidemic
·
Around 47,000 people died of opioid overdoses
in 2018
Purdue Pharma, the company that makes
OxyContin, will plead guilty to three federal criminal charges as part of a
settlement of more than $8 billion for its alleged role in fueling America's
opioid epidemic, Justice Department officials confirmed Wednesday.
United States Deputy Attorney General.
Jeffrey A. Rosen announced the deal in a press conference Wednesday morning as
he vowed to 'turn the tide on the opioid crisis ravaging the
country'. Rosen said the deal is still subject to bankruptcy court
approval.
Under the deal the Connecticut-based company,
owned by the wealthy Sackler family, will plead guilty to three criminal
charges filed in federal court in New Jersey Wednesday.
The three counts include conspiracy to
defraud the United States and violating federal anti-kickback laws.
The anti-kickback violation relates to a 2015
deal worth almost $1 million that the pharma giant made with electronic
health record company Practice Fusion to send alerts to doctors recommending
prescribing opioiods including Oxycontin to patients in order to increase
prescriptions of the drugs.
The deal does not release any of the
company's executives or owners - including members of the Sackler family - from
criminal liability and a criminal investigation is still ongoing.
However, if the bankruptcy court approves the
resolution, the Sackler family will lose any stake in the pharma giant and the
company will be dissolved as it currently stands, with its assets re-purposed
into a public company instead.
The settlement is the highest-profile display
yet of the federal government seeking to hold a major drugmaker responsible for
the opioid addiction and overdose crisis that has been linked to more than 430,000
deaths in the country since 2000.
Since OxyContin was introduced in 1996,
addiction and overdoses have surged.
In 1999 there were less than 4,000 opioid
overdose deaths. By 2018, this figure had risen to 47,000, according to the US
Centers for Disease Control and Prevention.
The DOJ announced what it described as a
'global resolution' of both its criminal and civil investigations into Purdue
and a 'civil resolution' of its civil investigation into individual
shareholders from the Sackler family.
Under the plea, Purdue will admit that from
May 2007 through at least March 2017 it conspired to defraud the US.
This charge relates to Purdue impeding the
Drug Enforcement Administration (DEA) by falsely representing that it had
maintained an effective program to avoid drug diversion, the officials said.
Rosen said the pharma giant had claimed to
have an effective anti-diversion program when it was actually continuing to
market its opioids to more than 100 healthcare providers who the company had
good reason to believe were diverting the drugs.
Purdue also reported misleading information
to the agency to boost the company's manufacturing quotas, said
Rosen.
Purdue will also admit to violating federal
anti-kickback laws by paying two doctors through a speaking program to write
more prescriptions for the company's opioids between June 2009 and March 2017,
the DOJ said.
The charge also relates to an illegal
kickback from around April 2016 to December 2016, according to the
officials.
DOJ officials said Purdue made payments to
electronic health records software firm Practice Fusion to influence the
prescription of pain medication.
In 2016, Purdue negotiated with Practice
Fusion to create a series of alerts in the software to get doctors to
increase prescriptions of opioids, they said.
The company agreed to pay nearly $1 million
to Practice Fusion in exchange for embedding alerts in its software for one
year.
Video playing bottom
right...
Click here to expand to
full page
Loaded:
0%
Progress:
0%
0:07
Pause
Unmute
Current Time0:07
/
Duration Time1:40
Fullscreen
Close
The drug giant described the move as a
'marketing tactic that would drive ERO demand and grow ERO
prescriptions.'
The civil settlement relates to both Purdue
and individual shareholders - members of the Sackler family.
Purdue will make a direct payment to the
government of $225 million, which is part of a larger $2 billion criminal
forfeiture.
The $225 million will be paid by the Sackler
family for the alleged conduct of Dr. Richard Sackler, David Sackler, Mortimer
D.A. Sackler, Dr. Kathe Sackler, and Jonathan Sackler, the DOJ said.
This settlement resolves allegations that, in
2012, those Sackler family members knew the legitimate market for
Purdue's opioids had contracted but requested executives recapture lost sales
and increase the company's share of the opioid market.
The family members then approved a new
marketing program in 2013 called 'Evolve to Excellence,' where sales reps for
the company upped their marketing of OxyContin to high-volume prescribers who
were already writing '25 times as many OxyContin scripts' as their peers, said
the DOJ.
The Justice Department said this led to
healthcare providers prescribing the highly-addictive drugs for uses that were
unsafe, ineffective, and medically unnecessary, and that often led to abuse and
diversion.
In addition to that forfeiture, Purdue also
faces a $3.54 billion criminal fine, though that money probably will not be
fully collected because it will be taken through a bankruptcy, which includes a
large number of other creditors.
Purdue will also agree to $2.8 billion in
damages to resolve its civil liability.
This relates to allegations that from 2010 to
2018, Purdue caused false claims to be submitted to federal health care
programs, including Medicare and Medicaid.
Purdue would transform into a public benefit
company, meaning it would be governed by a trust that has to balance the
trust's interests against those of the American public and public health, the
officials said.
The Sacklers would not be involved in the new
company and part of the money from the settlement would go to aid in medically
assisted treatment and other drug programs to combat the opioid epidemic, the
officials said.
That arrangement mirrors a key element of the
company's proposal to settle about 3,000 lawsuits filed by state, local and
Native American tribal governments.
Opioid overdose deaths triple
among US teens and young children
Kate Randall
Opioid
overdose death rates among US teens and children have tripled over the past 17
years, a new study shows. The study, published online in JAMA Network
Open, examined a group of almost 9,000 children and adolescents (under age 20)
who died in all settings from opioid poisonings between 1999 and 2016.
Researchers
found that young children have either died from accidentally ingesting
narcotics or from intentional poisoning. Teens, meanwhile, have more often died
from unintentional overdoses, using prescriptions painkillers found in their
homes or drugs bought on the streets. These include prescription opioids,
heroin, fentanyl and other legal and illicit drugs.
Julie
Gaither, lead researcher of the study and an instructor at the Yale School of
Medicine, told MedicalXpress, “These deaths don’t reach the magnitude of adult
deaths from opioids, but they follow a similar pattern.” She added, “As we
consider how to contain this epidemic, parents, clinicians and prescribers need
to consider how children and adolescents are affected and how our families and
communities are affected.”
The
study shows the depth of the opioid crisis facing the youngest segments of the
population and points to the woefully inadequate response of the government in
dealing with this social catastrophe as it spirals out of control.
The
study notes: “What began more than two decades ago as a public health problem
primarily among young and middle-aged white males is now an epidemic of
prescription and illicit opioid abuse that is taking a toll on all segments of
US society, including the pediatric population.”
Drug
overdose deaths in the US topped 72,000 in 2017, according to estimates released earlier this year by
the Centers for Disease Control and Prevention. This staggering figure was
6,000 more deaths than 2016 estimates, a rise of 9.5 percent. Some 43,000 of
drug overdose deaths in 2016, the latest year examined by the JAMA study, are
attributed to opioid overdoses. Other causes include alcohol poisoning and
other drug overdoses.
The
study categorized children and adolescents by the following ages: 0 to 4, 5 to
9, 10 to 14, and 15 to 19 years. Deaths in these age groups were then
classified according to intent: unintentional, suicide, homicide, and
undetermined intent. The study based its findings on death certificates since
1999.
A
total of 8,986 children and adolescents died from prescription and opioid
poisonings between 1999 and 2016: 605 (or 6.7 percent) among ages 0–4; 96 (1.1
percent) ages 5–9, 364 (4.1 percent) ages 10–14 and 7,921 (88.1 percent) ages
15–19. Among those under age 20, the annual estimated mortality rate from
opioids more than tripled during this period—rising from 0.22 per 100,000 in
1999 to 0.81 per 100,000 in 2016.
The
largest changes were seen among the oldest and youngest children. Teenagers
ages 15–19 had by far the highest death rates from opioids, at 88.1 percent of
the total. Of these teen deaths, more than 85 percent were unintentional. In
other words, while some teens deliberately overdose, others, seeking escape
from the stresses of unemployment, peer pressure, school demands, and college
admissions and debt, are falling victim to the wide availability and lethal
potency of both legal and illegal opioids.
While
some deaths can be blamed on unscrupulous drug dealers, these deaths must above
all be laid at the feet of the multibillion-dollar pharmaceutical companies who
have flooded neighborhoods with these potent opioids. Workers and professionals
who have been prescribed these drugs become the unwitting suppliers to their
children, who find them in home medicine cabinets and ingest them, lacking
adequate knowledge of the dangers they pose.
The
605 deaths among children ages 0 to 4 is the second highest, accounting for 6.7
percent of all pediatric deaths. Two hundred thirty of these deaths were
unintentional, while the manner of death could not be determined in 227 of
these cases.
However,
148 deaths in this age group, about one-quarter of the total, were due to
homicide. And the percentage of deaths due to homicide was highest for those
younger than 1 year, standing at 34.5 percent of this age group. Behind this
appalling statistic stands the social desperation that would drive a parent or
caregiver to kill an innocent infant with the aid of opioids. There are no
figures that indicate how many of these young victims have been born addicted
to opioids themselves.
While
the study found that the majority of pediatric deaths were among non-Hispanic
white males, with each passing year non-Hispanic black children accounted for a
larger proportion of fatalities. While white children saw a threefold increase
in deaths, black children had a nearly fourfold increase.
A
similar trend has been seen for female children, among whom death rates
increased more than threefold compared with a twofold increase among males.
These trends mirror those seen in the adult population, where deaths due to
opioids have been rising at a faster rate than among blacks and women than
among white men.
In
line with the opioid crisis affecting the US adult population, the devastating
toll of opioid deaths among children casts a grim light on 21st century
America. While the opioid crisis spares no segment of society, the most
profoundly affected are workers and the poor and the communities where they
live. At the root of this crisis lies a society characterized by growing social
inequality, corporate greed and profound government indifference.
In
2017, the Trump administration declared the opioid epidemic a “public health
emergency,” but then allocated no new funding to the states to address it. In
September, congressional Democrats and Republicans approved compromise legislation that purports to address the
opioid crisis, but the bill is primarily focused on law enforcement. It
allocates as little as $8 billion over five years, or roughly $1.6 billion per
year—a pittance given the dimensions of the epidemic.
A
health emergency on the scale of the drug epidemic requires an emergency,
socialist response. The giant pharmaceutical companies, who are responsible for
the scourge of opioid addiction and deaths, must be transformed into publicly
owned utilities. The health insurance industry, which dedicates its resources
to denying coverage and treatments instead of curing the ill, must be abolished
and replaced with universal, socialized medicine.
+4
HOW IS
OXYCONTIN IMPLICATED IN THE US OPIOID CRISIS?
OxyContin is a prescription painkiller produced and sold
by Purdue Pharma.
The drug is strong, addictive and was linked to thousands
of overdose deaths in 2017.
Since OxyContin, a time-released opioid, was introduced
in 1996, addiction and overdoses have surged.
In both 2017 and 2018, opioids were involved in more than
47,000 deaths, according to the US Centers for Disease Control and Prevention.
In 1999, by comparison, there were fewer than 4,000 opioid overdose deaths.
Purdue's drugs are just a slice of the opioids
prescribed, but critics assign a lot of the blame to the company because it
developed both the drug and an aggressive marketing strategy.
As part
of the plea deal, the company admits it violated federal law and 'knowingly and
intentionally conspired and agreed with others to aid and abet' the dispensing
of medication from doctors 'without a legitimate medical purpose and outside
the usual course of professional practice,' according to a copy of the plea
agreement obtained by the AP.
The
company is also required to cooperate with the ongoing federal investigation
and potential other prosecutions.
But
even before the deal was announced, it was facing resistance from state
attorneys general, Democratic members of Congress and advocates who wrote
Attorney General William Barr asking him not to make the bargain with the
company and the family.
They
said it does not hold them properly accountable and they raised concerns about
some of the details.
'Millions
of American families impacted by the opioid epidemic are looking to you and
your Department for justice.
'Justice
for the sleepless nights spent worrying about sons and daughters trapped in the
grip of substance use disorder, justice for the jobs lost and the lives ruined,
and justice for the lives of loved ones lost to overdoses,' 38 Democratic members
of Congress wrote.
'If the
only practical consequence of your Department´s investigation is that a handful
of billionaires are made slightly less rich, we fear that the American people
will lose faith in the ability of the Department to provide accountability and
equal justice under the law.'
The
Sackler family has already pledged to hand over the company itself plus at
least $3 billion to resolve thousands of suits against the Stamford,
Connecticut-based drugmaker.
The
company - but not the family - declared bankruptcy as a way to work out that
plan, which could be worth $10 billion over time.
About
half the states oppose that settlement, and also wrote Barr to ask him not to
make the federal deal that includes converting Purdue into a public benefit
corporation.
They
say it would be wrong for governments to rely on earnings from the sale of more
OxyContin to fund programs to mitigate the toll of an opioid crisis wrought by
prescription drugs as well as heroin and illicitly produced fentanyl.
With the
terms of the Justice Department deal, the federal government gives a strong
endorsement to the idea of a version of Purdue continuing as a 'public benefit
corporation.'
If that
plan does not end of being the heart of the reorganization through bankruptcy
court, the US could make Purdue pay it more, potentially unraveling any other
settlement arrangement.
The
state governments that oppose the settlements are pushing in bankruptcy court
for documents that would spell out how much Sackler family members made from
the sale of OxyContin over the years.
Officials,
who were not authorized to discuss the investigation publicly and spoke on
condition of anonymity, told the Associated Press about the deal ahead of the
DOJ press conference.
The
Sackler family was once listed among the nation's wealthiest by Forbes
magazine.
A 2019
court filing said they had made up to $13 billion over the years from the
blockbuster drug, though a lawyer said they brought in far less after taxes and
reinvestment in the company.
Until
recently, the family's name was on museum galleries and educational programs
around the world because of gifts from family members.
But
under pressure from activists, institutions from the Louvre in Paris to Tufts
University in Massachusetts have dissociated themselves from the family in the
last few years.
It's
not the first time Purdue has admitted wrongdoing.
The
company and three executives pleaded guilty to federal criminal charges in 2007
and paid more than $630 million in a settlement.
But after
that, the nation's addiction crisis only deepened.
As the
maker of the best-known prescription opioid, Purdue is the highest-profile
player in the opioid crisis, but it's far from the only one.
Trials
against other drugmakers and distributors that were scheduled for this year
have been pushed back due to the coronavirus.
WHO ARE THE
SACKLERS?
Purdue Pharma, which is run by some members of the
wealthy Sackler family, has made tens of billions on opioid sales. Here is a
breakdown of who the Sacklers are, including those who have and haven't been
involved in Purdue Pharma:
ARTHUR SACKLER
Arthur, a doctor and psychiatrist, founded a research laboratory in
1938, but Arthur's real genius was in marketing and he leveraged it to sell a
number of medications, including the anti-anxiety drug, Valium.
He and his younger brothers Mortimer and Raymond owned a small pharma
company called Purdue Frederick that they purchased in 1952. That
company produced betadine and earwax.
Arthur remained a relatively silent partner in the old Purdue and died
in 1987 before it became the company we know it as today.
He never saw any of Purdue's OxyContin profits.
He donated the funds to open a number of medical education programs,
libraries and museums.
Arthur was inducted into the Medical Marketing Hall of Fame upon his
death in 1987.
After his death in 1987, his brothers bought Arthur's portion of the
company.
One of his four children, daughter Elizabeth, has largely taken over his
philanthropy work.
Arthur and his heirs have had no involvement in Purdue Pharma or
with OxyContin.
MORTIMER SACKLER
Mortimer was an American physician and psychiatrist.
He and his brothers, the older Arthur and the younger Raymond published
prolific medical research before buying a number of pharmaceutical companies,
including, in 1952, Purdue Frederick.
After Arthur's death Mortimer and Raymond bought out his descendants'
share of Purdue Frederick, and in 1991 they created the company that would
become a pain management giant we now know, Purdue Pharma.
Mortimer became a lavish arts patron, known for equally extravagant
donations and parties, beginning in the 1970s.
He died in 2010.
RAYMOND SACKLER
Raymond was a doctor like his older brothers, and the three were partners
in all things until each of their deaths.
Together with Mortimer, Raymond found success with their opioid
painkiller, OxyContin, which became the Purdue Pharma's signature drug.
Raymond was milder and more private than his brother, Mortimer.
Raymond had two children, Richard and Jonathan, before his death last
year.
ILENE SACKLER
Mortimer's eldest daughter with his first wife.
She was listed as a director of Purdue's sister company, UK-based Napp
Pharamaceutical Holdings, as of December 2016.
She lives in an apartment in an iconic Upper West Side which she owns.
Its total value is estimated to be more than $122million.
KATHE SACKLER
Kathe is one of the directors of Napp, a UK-based company which also
sold OxyContin.
She owns two suburban properties in Connecticut which are separated by
another owned by someone else and she lives in an Upper East Side townhouse
with her wife, Susan Shack Sackler.
The house was owned by both Raymond and Mortimer. Their children
share it.
Kathe and Ilene had a brother, Robert, is deceased.
JONATHAN AND RICHARD SACKLER
They are Raymond and Beverly's two sons.
Jonathan and his wife live in Greenwich, Connecticut, in a property next
to his mother's. Richard 's former family home is not far away in neighboring
Stamford.
They have a cancer research center named after them at Yale and have
both held positions at Purdue.
RICHARD SACKLER
Richard Sackler followed in his father's footsteps, getting his medical
degree at New York University School of Medicine.
He came to Purdue after medical school, leading the research and
development that ultimately produced the extended release form of OxyContin
that would elevate the family's fortune to previously unfathomable.
He became president of Purdue in 1991, pioneering marketing campaigns
that enticed droves of medical professionals to buy Purdue's opioid.
Richard became co-chairman in 2003, by which point $1.6 billion in
OxyContin had been sold.
His marketing schemes sparked suspicion, and in 2015, Richard was deposed
before his company paid out a $24 million settlement.
The company appealed in 2017, but the case has not moved forward.
In addition to his arts philanthropy, Richard's foundations have donated
to controversial causes, including anti-Muslim groups.
ELIZABETH SACKLER
Arthur's daughter has publicly and persistently attempted to distance
herself from branch of her family that has profited from OxyContin.
Elizabeth is a licensed psychiatrist and well-known
philanthropist.
She is the founder of an eponymous Center for Feminist Art at the
Brooklyn Museum in New York.
She has previously expressed disgrace for her uncles' business.
Elizabeth has previously told DailyMail.com: 'I, nor my siblings,
nor my children have ever owned or benefited from Purdue Pharma or OxyContin or
oxycodone.
'It's another branch of the family.'
BEVERLY AND THERESA
SACKLER
Theresa, 69, owns a $45million Upper East Side apartment building
but lives mostly in the UK on a 10-acre estate in the Berkshire
countryside.
She is known in the UK as Dame Theresa Sackler, a title she was awarded
for her sustained philanthropy and support of the arts.
Theresa is more visible than her sister-in-law.
Beverly, 94, is Raymond's widow. She lives on a Greenwich, Connecticut
waterfront estate which has an estimated land and property value of almost
$50million. She also owns a 17-floor Fifth Avenue building in
Manhattan.
When her husband was still alive, they donated the Raymond and Beverly
Sackler Institute for Biological, Physical and Engineering Sciences at Yale. It
now employs 50 people across 20 departments.
MORTIMER DAVID ALFONS SACKLER
Mortimer the only son of founding brother Mortimer, Mortimer II's mother
is Gertraud Wimmer, Mortimer's second wife.
Mortimer David owns a luxury condo building in Boston and lives in New
York City with his 42-year-old wife Jacqueline.
The couple are a regular fixture on the Manhattan social circuit.
DAVID AND JOSS SACKLER
David is intensely private but his wife, Joss, is not.
She runs the members-only women's social club, LBV.
Among its events are group workouts at the model haven gym Dog Pound and
talks such as 'how to have the money talk with your kids.'
No comments:
Post a Comment